已发表论文

基于葡聚糖的可生物降解纳米粒子:创伤性脊髓损伤治疗的一个备择而便捷的策略

 

Authors Liu W, Quan P, Li Q, Tang P, Chen J, Jiang T, Cai W

Received 22 April 2018

Accepted for publication 5 June 2018

Published 13 July 2018 Volume 2018:13 Pages 4121—4132

DOI https://doi.org/10.2147/IJN.S171925

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Dr Linlin Sun

Introduction: After traumatic spinal cord injury (SCI), an inhibitory environment that contains chondroitin sulfate proteoglycans (CSPGs) is formed that prevents axonal regeneration and growth.
Materials and methods: As previously reported, local administration of Taxol® at a low concentration has shown promising abilities to promote axonal regeneration and downregulate inhibitory molecules after acute SCI. However, the application of an invasive miniosmotic pump to deliver Taxol and the Cremophor-related toxicity caused by Taxol limits the administration of Taxol.
Results: In this study, the sustained release of paclitaxel (PTX) for 7 days was achieved by incorporating PTX into acetalated dextran (Ac-DEX) nanoparticles, and the prepared PTX-loaded Ac-DEX (PTX@Ac-DEX) nanoparticles promoted neurite extension in the presence of CSPGs. In a rat SCI model, both PTX@Ac-DEX and Taxol enhanced neural regeneration, inhibited CSPGs, protected the injured spinal cord, and improved locomotor recovery. Because of the sustained release of PTX, single administration of PTX@Ac-DEX showed equal therapeutic effect with Taxol, which need to be administered for seven days using a surgically implanted miniosmotic pump.
Conclusion: Overall, this study provides an effective and convenient strategy for SCI therapy, which can improve neurite extension across an inhibitory environment and avoid Cremophor-related toxicity caused by Taxol.
Keywords: acetalated dextran, nanoparticle, paclitaxel, spinal cord injury




Figure 3 In vitro viability and neuroprotective effect of PTX@Ac-DEX (n=6).